Form 4: BioMarin Executive Sells 4,000 Shares Under 10b5-1 Plan

Jeffrey Robert Ajer, EVP and Chief Commercial Officer of BioMarin Pharmaceutical Inc., sold 4,000 shares of common stock at $87.07 per share on March 5, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On March 5, 2024, Jeffrey Robert Ajer, the EVP and Chief Commercial Officer of BioMarin Pharmaceutical Inc. (BMRN), sold 4,000 shares of the company's common stock.
• The sale was executed at a price of $87.07 per share.
• The transaction was conducted under a pre-existing 10b5-1 trading plan established on April 13, 2023.
• Following the transaction, Ajer directly owns 94,047 shares of BioMarin common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an executive stock sale under a pre-arranged plan. It doesn't inherently convey positive or negative sentiment.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies. They can be driven by various factors, including personal financial planning and diversification. The use of 10b5-1 plans allows insiders to sell shares over a period of time without being accused of trading on inside information.

Stakeholder Impact

• The stock sale by an executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates